Pulse Biosciences’ First Study in a Surgical Application of Nanosecond Pulsed Field Ablation (nsPFA) Technology to be Featured in Two Poster Presentations at the American Thyroid Association Annual Meeting
September 27 2023 - 8:00AM
Business Wire
First prospective clinical feasibility study suggests nsPFA may
be a safe and effective method for treating benign thyroid tumors
or nodules
Pulse Biosciences, Inc. (Nasdaq: PLSE, “the Company”), a company
primarily focused on leveraging its novel and proprietary
Nanosecond Pulsed Field Ablation (nsPFA) technology for the
treatment of atrial fibrillation, today announced its nsPFA
technology will be featured in two poster presentations at the
upcoming American Thyroid Association 2023 Annual Meeting in
Washington D.C. from September 27th to October 1st, 2023.
“I am proud to have been a part of the first human surgical
procedure study on benign thyroid nodules conducted with the nsPFA
technology. In the treated regions, we observed complete ablation
of the cellular tissue without evidence of thermal necrosis or
damage to noncellular structures, as is typically the case with
current thermal treatment modalities,” said Dr. Stefano Spiezia,
Chief of Endocrine Surgery Division at Napoli Ospedale del Mare and
principal investigator of the study. “We look forward to sharing
these promising results with our esteemed colleagues at the ATA
meeting and continuing our work with nsPFA.”
“The findings from this study are extremely compelling and
suggest that nsPFA could represent a significant advancement in the
treatment of symptomatic benign thyroid nodules,” said Dr. Ralph
Tufano, Director of Head and Neck Endocrine Surgery at Sarasota
Memorial Health Care System. “The exciting possibility of a new
energy modality with improved speed and safety around critical
structures, such as nerves and blood vessels, could be a
game-changer for many of these patients."
Late Breaking Abstract Poster Presentations #517 First
Prospective Clinical Feasibility Study Using Nanosecond Pulsed
Field Ablation (nsPFA) for the Treatment of Benign Thyroid Nodules
– Histological Assessment S. Spiezia, C. Offi, C. Misso, G.
Antonelli, A. D’Antonio, R. P. Tufano and W. A. Knape Advantages of
nsPFA technology includes cellular tissue selectivity, sharp
ablation zone margins, absence of thermally induced necrosis, and
short treatment times. This feasibility study suggests nsPFA may be
a safe and effective method for treating benign thyroid tumors or
nodules.
#518 First Prospective Clinical Feasibility Study Using
Nanosecond Pulsed Field Ablation (nsPFA) for the Treatment of
Benign Thyroid Nodules – Ultrasound Assessment S. Spiezia, C. Offi,
C. Misso, G. Antonelli, A. D’Antonio, R. P. Tufano and W. Knape
This feasibility study suggests nsPFA may be a safe and effective
method for treating benign thyroid tumors or nodules.
About Pulse Biosciences®
Pulse Biosciences is a novel bioelectric medicine company
committed to health innovation that has the potential to improve
the quality of life for patients. The Company’s proprietary
Nanosecond Pulsed Field Ablation (nsPFA) technology delivers
nanosecond pulses of electrical energy to non-thermally clear cells
while sparing adjacent noncellular tissue. The Company is actively
pursuing the development of its nsPFA technology for use in the
treatment of atrial fibrillation and in a select few other markets
where nsPFA could have a profound positive impact on healthcare for
both patients and providers.
Pulse Biosciences, CellFX, Nano-Pulse Stimulation, NPS, nsPFA
and the stylized logos are among the trademarks and/or registered
trademarks of Pulse Biosciences, Inc. in the United States and
other countries.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230927931125/en/
Investor Contacts: Pulse Biosciences Kevin Danahy,
President and CEO 510.241.1077 IR@pulsebiosciences.com or Gilmartin
Group Philip Trip Taylor 415.937.5406 philip@gilmartinir.com
Pulse Biosciences (NASDAQ:PLSE)
Historical Stock Chart
From Jul 2024 to Aug 2024
Pulse Biosciences (NASDAQ:PLSE)
Historical Stock Chart
From Aug 2023 to Aug 2024